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DockingAbstract A novel series of compounds containing tertiary amine moiety, substituted benzimida-
zole and triazole ring, initial design by molecular docking study of this scaffold at the active site
of the fungal enzymes lanosterol 14a-demethylase (homology modeled of C. albicans) was synthe-
sized by microwave irradiation and characterized by Proton Nuclear Magnetic Resonance
(1H NMR), Infra Red (IR), and Mass Spectroscopy (MS), and by elemental analysis. The screening
of compound for in vitro (turbidimetric method) and in vivo (kidney burden test) antifungal activity
against C. albicans revealed activity in many of the compounds as comparable to that of ﬂucona-
zole.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf of King SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In the past few decades, the incidence of life-threatening fungal
infections caused by pathogenic fungi is becoming alarming.
This scenario is being observed among individuals with sup-
pressed immune systems brought about by the use of cytotoxic
drugs, immunosuppressive therapy, or human immunodeﬁcien-
cy virus infection (Ting and Walker, 2008). These infectionshave also been observed in some iatrogenic or nosocomial
clinical settings. Autopsy data indicate that more than half of
the patients who die with malignancies are infected with
Candida spp., approximately one-third with Aspergillus spp.,
and increasing numbers with Cryptococcus spp. or other fungi
such as Fusarium spp. The major opportunistic pathogen has
been C. albicans (Pfaller and Diekema, 2004). Although several
superior antifungal drugs are available for the treatment of
these life threatening infections they still demonstrate draw-
backs such as water solubility, narrow spectrum and serious
toxic side effects such as pruritis, gastrointestinal upset,
thrombophlebitis, drug interference, bioavailability, and
hepatotoxicity (Hester et al., 2004).
The major thrust of medicinal chemist in the area of anti-
fungal chemotherapy for the last two decades has been focused
on a group of heterocyclic compound generally referred to as
the ‘azoles’. Conventional azoles including chlormidazoleole ana-
Figure 1 Design of benzimidazole tertiary amine type of ﬂuconazole analogues.
2 R.S. Kankate et al.(Erik et al., 1967), miconazole (Jiang et al., 2005), clotrimazole
(Frye and Robinson, 1988), and ketoconazole (Brown et al.,
1976) were highly substituted imidazoles. However, the struc-
ture activity studies have shown that 1,2,4-triazole ring (ﬂu-
conazole, voriconazole, and albaconazole) enhances the
selectivity for binding with lanosterol 14a-demethylase without
adversely affecting the antifungal properties of the molecule
(Groll and Lumb, 2012). Azole antifungal drugs show their
action by the inhibition of lanosterol 14a-demethylase in the
process of biosynthesis of ergosterol through a mechanism in
which the heterocyclic nitrogen atom (N-4 of triazole) binds
to the heme iron atom (Sheehan and Hitchcock, 1999).
However, the increasing administration of antifungal drugs
has led to the development of resistance to these drugs. A sur-
vey by Pfaller et al. revealed that genetic mutations are possi-
bly responsible for the resistance to clinically used drugs
especially ﬂuconazole (Pfaller et al., 2001). In addition, resis-
tance to new structurally related azoles such as voriconazoleTable 1 Ramachandran plot values showing number of residue
evaluation server.
Structure Number of residues in
favoured region (%)
4K0F 98
MODEL BUILT 96.6
Please cite this article in press as: Kankate, R.S. et al., Design, synthesis and antifu
logues. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015(Jeu et al., 2003), and ravuconazole (Lepesheva et al., 2006)
has also been observed in other studies. A perusal of literature
revealed that tertiary amine moiety, benzimidazole and tria-
zole rings were signiﬁcant structural moieties for antifungal
activity (Ates-Alagoz et al., 2005; Herna´ndez-Luis et al.,
2010; O¨zkay et al., 2010; Pawar et al., 2004; Jain et al., 2014;
Mavrova et al., 2007; Garuti et al., 2000; Le et al., 2004;
Thakurdesai et al., 2007; Ram et al., 1992; Abdel-monem
Abdel-hafez, 2007; Gu¨llerman et al., 2001; Maxwell et al.,
1984; Sangshetti et al., 2011; Zhang et al., 2013; Wang et al.,
2012). In view of the previous evidence available for bioactive
benzimidazoles, the present study aimed to redesign the struc-
ture of ﬂuconazole in several aspects as illustrated in Fig. 1.
Benzimidazole (imidazole ring fused to the benzene ring
with a large conjugated system and a superior electro rich
properties in comparison with triazole and imidazole) moiety,
a bioisosteres was selected to replace triazole of ﬂuconazole to
evaluate the effect of substituted N1 and C2 benzene fusedin the favoured allowed, outlier region through RAMPAGE
Number of residues in
allowed region (%)
Number of residues in
outlier region (%)
2 0
3.0 0.4
ngal evaluation of novel benzimidazole tertiary amine type of ﬂuconazole ana-
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Table 2 Molecular docking data of synthesized compounds compared with ﬂuconazole.
Compound code Lig score 1 Lig score 2 -PLP1 -PLP2 Jain PMF Dock score Distance of N4 from heme iron (A˚)
10a 2.81 2.97 58.54 64.36 1.3 52.72 32.622 3.009
10b 3.02 4.12 56.12 54.24 1.55 49.27 44.843 3.140
10c 3.69 5.51 79.96 86.31 2.8 51.14 32.789 3.226
10d 3.2 3.96 76.84 75.18 3.32 72.14 33.184 2.166
10e 1.79 1.81 52.73 50.28 4.13 46.35 43.97 3.198
10f 3.51 3.6 83.14 83.77 3.1 54.65 31.419 2.670
10g 1.74 1.69 87.76 100.88 5.34 65.35 22.154 3.010
10h 1.42 1.44 48.57 43.52 3.58 58.21 37.079 3.093
10i 5.11 5.65 88.53 82.15 2.7 68.64 51.448 2.243
10j 2.9 3.25 60.81 65.10 3.12 62.14 36.25 2.080
10k 1.96 2.52 54.32 49.24 3.96 44.58 41.90 3.159
10l 4.49 3.65 80.12 79.25 3.72 58.66 42.16 2.510
Fluconazole 5.17 5.19 73.88 65.13 1.19 62.97 54.846 2.392
Table 3 Effect of synthesized compounds against C. albicans
by serial dilution method.
Compounds Concentration (lmol/ml)
0.5 0.25 0.125 0.06 0.03 0.015 0.0076
10a  + + + + + +
10b     + + +
10c     + + +
10d    + + + +
10e     + + +
10f     + + +
10g      + +
10h       +
10i       
10j      + +
10k       +
10l       +
Fluconazole       
() Indicates absence of growth; (+) Indicates presence of growth;
Table 4A In-vivo anti fungal activity of synthesized com-
pounds (Mortality in hours).
Group Treatment Mortality (x/5)
1 h 2 h 4 h 6 h 12 h 24 h
1 Vehicle 0/5 0/5 0/5 1/5 2/5 2/5
2 Standard (0.42 mg/kg) 0/5 0/5 0/5 0/5 0/5 0/5
3 10a-0.26 mg/kg 0/5 0/5 0/5 0/5 0/5 0/5
5 10a-0.42 mg/kg 0/5 0/5 0/5 0/5 0/5 0/5
5 10b-0.26 mg/kg 0/5 0/5 0/5 0/5 0/5 1/5
6 10b-0.42 mg/kg 0/5 0/5 0/5 0/5 0/5 0/5
7 10c-0.26 mg/kg 0/5 0/5 0/5 0/5 1/5 1/5
8 10c-0.42 mg/kg 0/5 0/5 0/5 0/5 0/5 1/5
9 10d-0.26 mg/kg 0/5 0/5 0/5 0/5 1/5 1/5
10 10d-0.42 mg/kg 0/5 0/5 0/5 0/5 0/5 1/5
11 10e-0.26 mg/kg 0/5 0/5 0/5 0/5 0/5 0/5
12 10e-0.42 mg/kg 0/5 0/5 0/5 0/5 0/5 0/5
13 10f-0.26 mg/kg 0/5 0/5 0/5 1/5 2/5 2/5
14 10f-0.42 mg/kg 0/5 0/5 0/5 0/5 1/5 1/5
15 10g-0.26 mg/kg 0/5 0/5 0/5 0/5 0/5 1/5
16 10g-0.42 mg/kg 0/5 0/5 0/5 0/5 0/5 0/5
17 10h-0.26 mg/kg 0/5 0/5 0/5 0/5 1/5 1/5
18 10h-0.42 mg/kg 0/5 0/5 0/5 0/5 0/5 1/5
19 10i-0.26 mg/kg 0/5 0/5 0/5 0/5 1/5 1/5
20 10i-0.42 mg/kg 0/5 0/5 0/5 0/5 0/5 1/5
Design, synthesis and antifungal evaluation of benzimidazole tertiary amine type 3imidazole ring on antifungal activity (Luo et al., 2009;
Nowakowska et al., 2008). Benzimidazole ring could readily
interact with active target in biological system via diverse
non-covalent interactions such as hydrogen bond, p–p
stacking, and hydrophobic effect as well as Vander Waals
force. Addition of functional groups to the benzimidazole ring
has resulted in interaction with extra binding region in binding
site (Khalaﬁ-Nezhad et al., 2005).
In the present study, we evaluated the effect of benzimida-
zole by substitutions at N-1, C2 and C5 positions. The follow-
ing variations in the benzimidazole ring were evaluated in this
study:
 Methyl substitution at N1.
 C5 is normally substituted with hydrogen/hydroxyl/
chlorine.
 Substituent at C2 methylene/a-substituted ethyl/benzyl.
The compound with best binding interaction does not nec-
essarily imply to exhibit the best drug activity in medicine.
Additionally, the drug has to pass through various barriers
to reach the target site within the body. In order to achievePlease cite this article in press as: Kankate, R.S. et al., Design, synthesis and antifu
logues. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015the best activity, we replaced tertiary alcohol of ﬂuconazole
with bioisosteres tertiary amino moiety. The tertiary amino
group in comparison with the tertiary alcohol group was able
to not only form hydrogen bonds but also accept protons or
form quaternary salts which result in enhanced water solubility
(Khalaﬁ-Nezhad et al., 2005).
Several studies from the past have demonstrated that incor-
porating halobenzyl moiety into organic molecules could
greatly improve the pharmacological properties (Guven
et al., 2007; Tu¨rkmen et al., 2011; Karegoudar et al., 2008).
An enhanced pharmacological action results from an increased
rate of absorption, transport of drugs in vivo, and a higher lipid
solubility (Lin et al., 2005). The greater ﬂexibility of the benzyl
moiety as compared to phenyl group may show improved
molecular biological properties.
The methylene bridge between tertiary alcohol group and
triazolyl moiety in ﬂuconazole was replaced by ethylene/benzyl
to increase molecular ﬂexibility. This substitution may showngal evaluation of novel benzimidazole tertiary amine type of ﬂuconazole ana-
.02.002
Table 4B In-vivo anti fungal activity of synthesized com-
pounds (Mortality in days).
Group Treatment Mortality (x/5)
Day 0 Day 7 Day 14 Day 21
1 Vehicle 0/5 3/5 5/5 5/5
2 Standard (0.42 mg/kg) 0/5 0/5 0/5 0/5
3 10a-0.26 mg/kg 0/5 1/5 2/5 3/5
5 10a-0.42 mg/kg 0/5 1/5 2/5 2/5
5 10b-0.26 mg/kg 0/5 1/5 2/5 3/5
6 10b-0.42 mg/kg 0/5 0/5 1/5 2/5
7 10c-0.26 mg/kg 0/5 1/5 1/5 2/5
8 10c-0.42 mg/kg 0/5 0/5 1/5 1/5
9 10d-0.26 mg/kg 0/5 1/5 2/5 3/5
10 10d-0.42 mg/kg 0/5 0/5 1/5 2/5
11 10e-0.26 mg/kg 0/5 1/5 2/5 3/5
12 10e-0.42 mg/kg 0/5 0/5 1/5 2/5
13 10f-0.26 mg/kg 0/5 1/5 2/5 2/5
14 10f-0.42 mg/kg 0/5 0/5 1/5 1/5
15 10g-0.26 mg/kg 0/5 0/5 2/5 3/5
16 10g-0.42 mg/kg 0/5 0/5 1/5 2/5
17 10h-0.26 mg/kg 0/5 0/5 1/5 1/5
18 10h-0.42 mg/kg 0/5 0/5 0/5 1/5
19 10i-0.26 mg/kg 0/5 0/5 0/5 0/5
20 10i-0.42 mg/kg 0/5 0/5 0/5 0/5
21 10j-0.26 mg/kg 0/5 1/5 1/5 2/5
22 10j-0.42 mg/kg 0/5 0/5 0/5 1/5
23 10k-0.26 mg/kg 0/5 0/5 1/5 1/5
24 10k-0.42 mg/kg 0/5 0/5 0/5 1/5
25 10l-0.26 mg/kg 0/5 0/5 1/5 2/5
26 10l-0.42 mg/kg 0/5 0/5 1/5 1/5
Table 4C In-vivo anti fungal activity of synthesized com-
pounds (Kidney Burden Test).
Group Treatment Log10 CFU/gm wet tissue
1 Vehicle 4.12 ± 0.036
2 Standard (0.42 mg/kg) 2.17 ± 0.122*
3 10a-0.26 mg/kg 3.98 ± 0.018*
5 10a-0.42 mg/kg 3.14 ± 0.086*
5 10b-0.26 mg/kg 3.78 ± 0.013*
6 10b-0.42 mg/kg 3.02 ± 0.027*
7 10c-0.26 mg/kg 3.08 ± 0.029*
8 10c-0.42 mg/kg 2.84 ± 0.086*
9 10d-0.26 mg/kg 3.42 ± 0.014*
10 10d-0.42 mg/kg 2.93 ± 0.017*
11 10e-0.26 mg/kg 3.82 ± 0.014*
12 10e-0.42 mg/kg 3.48 ± 0.013*
13 10f-0.26 mg/kg 3.04 ± 0.086*
14 10f-0.42 mg/kg 3.28 ± 0.013*
15 10g-0.26 mg/kg 3.83 ± 0.027*
16 10g-0.42 mg/kg 3.49 ± 0.016*
17 10h-0.26 mg/kg 2.96 ± 0.016*
18 10h-0.42 mg/kg 2.65 ± 0.029*
19 10i-0.26 mg/kg 2.60 ± 0.020*
20 10i-0.42 mg/kg 2.43 ± 0.049*
21 10j-0.26 mg/kg 3.55 ± 0.032*
22 10j-0.42 mg/kg 3.02 ± 0.051*
23 10k-0.26 mg/kg 2.92 ± 0.033*
24 10k-0.42 mg/kg 2.68 ± 0.045*
25 10l-0.26 mg/kg 2.92 ± 0.027*
26 10l-0.42 mg/kg 2.71 ± 0.036*
Values are expressed as MEAN± SD at n= 5, One way Anova
followed by Bonferroni test.
* P< 0.001 (signiﬁcant) compared to the vehicle.
4 R.S. Kankate et al.positive effect on the molecular binding ability to the microbial
target (Fang et al., 2010).
In view of above consideration and based on molecular
docking studies, we designed and synthesized a series of novel
tertiary amine type of substituted benzimidazole derivatives as
ﬂuconazole analogues using microwave irradiation. The newly
prepared derivatives were docked into the active site of homol-
ogy modeled CYP51 of C. albicans, using Accelrys, Discovery
Studio 2.1 Software, Inc., San Diego, CA. The chemical struc-
tures of the new derivatives were conﬁrmed by elemental and
spectral (1H NMR and Mass) analyses. All compounds were
investigated for in vitro and in vivo antifungal activities against
C. albicans.
2. Materials and methods
All materials were procured from Sigma Aldrich and Merck
specialties Pvt. Ltd. (Mumbai, India). Solvents were dried
and distilled being used. Anhydrous sodium sulfate was used
to dry the solvents. Syntheses were performed in a CEM
Discover monomode reactor and temperature was moni-
tored by a built-in infrared sensor. Thin layer chromatography
(TLC) analyses were carried out on aluminum plates (Merck)
precoated with silica gel 60 F254 (0.2 mm), and spots were
visualized with UV light and I2. Liquid intermediates were
checked for purity using gas chromatography (Pack column
SE-30, OV-101, and capillary column BP-5). Gravity column
chromatography was performed using silica gel (Merck 60).
Melting points were taken in open glass capillary using Elico
melting point apparatus and were uncorrected. Infra RedPlease cite this article in press as: Kankate, R.S. et al., Design, synthesis and antifu
logues. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015(IR) spectra were recorded on KBr pellets on a Shimadzu
1000 FTIR spectrometer in the range of 4000–200 cm1,
Resolution 2.0 with number of scan – 45. Apodization;
Happ-Genzel. Proton (1H) Nuclear Magnetic Resonance
(NMR) spectra of compounds were recorded on Bruker
Advance II 400 NMR Spectrophotometer using CDCl3 sol-
vent, at SAIF, Punjab University, Chandigarh. Mass spectra
of compounds were recorded on API 4000 Q TRAP LC/MS/
MS system using electron spray ionization positive ion mass
spectrometric technique, at NHRDF, Chitegaon, Nashik.
Elemental analyses were performed on a Perkin-Elmer 2400
Analyser and are within ±0.4% of theoretical values.
2.1. Synthesis of tertiary amine type of substituted
benzimidazole derivatives (Scheme 1)
2.1.1. Synthesis of 4-substituted (H/Cl) N1-methyl/ethyl-2-
nitroaniline (2a–2d)
It was synthesized by using 4-substituted (H/Cl) 2-ﬂuroni-
trobenzene 1a, 1b 25 ml (33.5 g, 0.24 mol) in dimethyl for-
mamide as solvent and (0.804 mol) anhydrous potassium
carbonate, (2.5 mol, 40% solution) of methylamine/ethylamine
was slowly added it through dropping funnel in cold condition.
After complete addition of methylamine/ethylamine solution
the reaction mixture was kept in microwave for 10 min. The
completion of reaction was checked by monitoring TLC. After
completion, the reaction mixture was poured into ice cold
water with stirring and extracted with the product with ether,
the ether layer was separated and dried with sodium sulfatengal evaluation of novel benzimidazole tertiary amine type of ﬂuconazole ana-
.02.002
Figure 2 Shows alignment between query and template sequence, identity is 55.9% and similarity 70.2%.
Design, synthesis and antifungal evaluation of benzimidazole tertiary amine type 5and then ether was removed by distillation to get products
(Willitzer et al., 1978).
2.1.2. Synthesis of 4-substituted N1-methyl/ethyl-o-
Phenylenediamine (3a–d)
4-substituted N1-methyl/ethyl-2-nitroaniline (2a, 2b) (5 mM),
zinc dust (0.25 g) and ammonium chloride (10 mM) in 5 ml
water were mixed thoroughly in a small beaker (25 ml). The
reaction solid mixture was placed in a microwave oven
(300 W) at 50% power level for 8–15 min, the progress of
the reaction was monitored by checking the solubility of the
solid reaction mixture product in dilute HCl, and when all
the organic solid dissolved it was ﬁltered to separate zinc dust,
and neutralized with aqueous solution. The solid was separat-
ed by ﬁltration and recrystallized from an appropriate solvent
(aqueous ethanol) (Abdullah and Suliman, 2011).Figure 3 Homology modeled structure of lanosterol 14-alpha
demethylase of Candida albicans.
Please cite this article in press as: Kankate, R.S. et al., Design, synthesis and antifu
logues. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.20152.1.3. Synthesis of 5-substituted 2-(chloromethyl)-1-methyl-1H-
benzo[d] imidazoles (4a–d)
In a typical experiment, (0.2 mole) 3a–d, (0.3 mole) of mono-
chloro acetic acid, 5 ml of hydrochloric acid and 25 ml of
methanol were taken in a round bottom ﬂask and then placed
in microwave irradiation at 250 W for 12 min. The reaction
was monitored by TLC. A test portion was added in water
and basiﬁed with ammonia solution. The solid was extracted
with ether and TLC of this ether extract was done to check
for completion of reaction. After completion, the reaction mix-
ture was poured into ice-cold water. It was then basiﬁed with
concentrated ammonia solution. The solid precipitate was
ﬁltered immediately and dried.
2.1.4. Synthesis of 5-substituted- 2-(a-hydroxyethyl/phenyl)-1-
methyl-1H-benzo[d] imidazoles (5a–h)
4-substituted N1-methyl-o-Phenylenediamine 0.036 mol
(3a–d), lactic/mandelic acid 0.054 mol, 5 ml of hydrochloric
acid and methanol were taken in a round bottom ﬂask and
then placed in microwave irradiation at 300 W for 15 min.
The reaction was monitored by TLC. Reaction completion
was monitored by TLC. Solution was allowed to stand over-
night, ﬁltered and the ﬁltrate was cooled by addition of ice.
It was then neutralized by careful addition of solid NaHCO3
by stirring. Product removed by ﬁltration, washed with water
and dried. Recrystallization was done using chloroform by
addition of charcoal.
2.1.5. Synthesis of 5-substituted- 2-(1-chloroethyl/phenyl)-1-
methyl-1H-benzo[d] imidazoles (6a–h)
The activation of carboxylic function was carried out by using
an excess of thionyl chloride and catalytic amount of dimethyl
formamide placed in an ice cold water bath. To this mixture,ngal evaluation of novel benzimidazole tertiary amine type of ﬂuconazole ana-
.02.002
Figure 4 (A) Ramachandran plot of 4K0F and (B) Ramachandran plot of modeled structure.
6 R.S. Kankate et al.15 g 2-a-hydroxy phenyl/ethyl-N1-methyl benzimidazole was
added slowly with occasional stirring. This mixture was then
placed in microwave irradiation at 250 W for 10 min. Excess
thionyl chloride was recovered under vacuum on a water bath.
To the residue dry dioxane was added and stirred for 30 min.
Dioxane was recovered under vacuum to get the ﬁnal product.
2.1.6. Synthesis of N-(chloromethyl)-2,4-diﬂuoroaniline (8)
This was done using 2,4-diﬂuroaniline (3 mmol) 7 and dichlor-
omethane (6 mmol) in H2O (1 ml) using microwave irradiation
at 150 C (power set point 150 W; ramp time 1 min; hold time
20 min). After cooling, the mixture was diluted with water
(500 ml), neutralized with NaHCO3, and fractionally distilled
at atmospheric pressure through an efﬁcient column, discard-
ing the ﬁrst fraction and then collecting the pure ﬁnal product
(Marzaro et al., 2009).
2.1.7. Synthesis of N-((1H-1, 2, 4-triazol-1-yl) methyl)-2,4-
diﬂuoroaniline (9)
1,2,4-triazole (10 mmol), NaOH (40 mmol), 2,4-diﬂuro aniline
derivative and DMF (10 ml) were stirred on magnetic stirrer
for 20 min and then placed in microwave oven for 10 min.
The reaction mixture was poured into 50 ml water to obtain
the solid precipitate.
2.1.8. Synthesis of N-(2,4-diﬂuorophenyl)-N-(1-(1,6-dimethyl-
1H-benzo[d]imidazol-2-yl)ethyl)-1H-1,2,4-triazol-1-amine
(10a–l)
In a typical experiment, 1 g (0.005 mol) of 2-chloromethyl/
ethyl/phenyl-N1-methylbenzimidazole, 1.47 g (0.005 mol)Please cite this article in press as: Kankate, R.S. et al., Design, synthesis and antifu
logues. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015of N-(1H-1,2,4-triazol-1-yl)methyl)-2,4-diﬂuoroaniline were
separately dissolved in dry dioxane and mixed in an round bot-
tom ﬂask. To this reaction mixture, 0.76 ml (0.005 mol) of tri-
ethylamine was added and the reaction mixture was reﬂuxed
for 30 min. The reaction was monitored by TLC. The reaction
mixture was then poured into ice cold water and the precipitate
was collected by suction and drying. The solid was recrystal-
lized from acetone.
2.2. Compound code
2.2.1. 10a: 2.2,4-diﬂuoro-N-((1-methyl-1H-benzo[d]imidazol-
2-yl)methyl)-N-(1H-1,2,4-triazol-1-yl) benzenamine
Compound 10a was obtained as a white solid (Yield: 76.35%;
MP: 114–116; IR (KBr): 3301 (CAN), 2365 (CAH), 1604
(C‚N), 1584 (NAN), 1556(C‚C), (CAF) 975 cm1; 1H
NMR (300 MHz, CDCl3) d ppm: 3.34 (s, 3H, NACH3), 4.39
(s, 2H, PhACH2), 6.45–6.51 (m, 3H, ArAH), 7.30–7.45 (m,
4H, ArAH of Benzim), 8.42 (s, 1H, N‚CHANACH of
1,2,4-Triazole); ESI–MS m/z: 340.12, 325.101, 272, 145. Anal.
Calcd. for C17H14F2N6 (340.33): C, 60.00; H, 4.15; F, 11.16; N,
24.69. Found: C, 60.07; H, 4.21; F, 11.26; N, 24.75.
2.2.2. 10b: 2, 4-diﬂuoro-N-(1-(1-methyl-1H-benzo[d]imidazol-
2-yl) ethyl)-N-(1H-1,2,4-triazol-1-yl) benzenamine
Compound 10b was obtained as a white solid, Yield: 68; mp:
121–123; IR (KBr): 3300 (CAN), 2361 (CAH), 1602 (C‚N),
1583 (NAN), 1551 (C‚C), (CAF) 972 cm1; 1H NMR
(300 MHz, CDCl3) d ppm: 1.49 (d, 1H, ACHAN), 3.18 (s,
3H, NACH3), 4.24 (q, 3H, AHCACH3), 6.43–6.51 (m, 3H,ngal evaluation of novel benzimidazole tertiary amine type of ﬂuconazole ana-
.02.002
Figure 5 (A) Plot of Z-score of 4K0F and (B) plot of Z-score of modeled structure.
Figure 6 RMSD between modeled structure and template of
0.38 A˚. Red color indicates modeled structure of lanosterol 14
alpha demethylase, and white indicates template structure K0F.
Design, synthesis and antifungal evaluation of benzimidazole tertiary amine type 7ArAH), 7.26–7.30 (d, 3H, ArAH of Benzim), 8.02 (s, 1H,
N‚CHANACH of 1,2,4-Triazole); ESI–MS m/z: 354.1,
339.117, 286.116, 195.048, 159.092. Anal. Calcd. for
C18H16F2N6 (354.1): C, 61.01; H, 4.55; F, 10.72; N, 23.72.
Found: C, 61.05; H, 4.50; F, 10.62; N, 23.
2.2.3. 10c: N-(2,4-diﬂuorophenyl)-N-((1-methyl-1H-benzo[d]
imidazol-2-yl)(phenyl)methyl)-1H-1,2,4-triazol-1-amine
Compound 10c was obtained as a white solid, Yield: 71%; mp:
158–160; IR (KBr): 3301 (CAN), 2365 (CAH), 1604 (C‚N),
1584 (NAN), 1556 (C‚C), (CAF) 975 cm1; 1H NMR
(300 MHz, CDCl3) d ppm: 3.62 (s, 3H, NACH3), 4.22 (s,
5H, ArAH), 6.39–6.46 (m, 3H, ArAH), 7.12–7.22 (d, 1H,
ACAH), 7.35–7.47 (d, 3H, ArAH of Benzim), 8.41 (s, 1H,
N‚CHANACH of 1,2,4-Triazole); ESI–MS m/z: 401.133,
221.108, 303.136. Anal. Calcd. For C23H18F2N6 (416.2):
C, 66.34; H, 4.36; F, 9.12; N, 20.18. Found: C, 66.24; H,
4.32; F, 9.18; N, 20.12.Please cite this article in press as: Kankate, R.S. et al., Design, synthesis and antifu
logues. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.20152.2.4. 10d: 2,4-diﬂuoro-N-((1-ethyl-1H-benzo[d]imidazol-2-yl)
methyl)-N-(1H-1,2,4-triazol-1-yl) benzenamine
Compound 10d was obtained as a white solid (Yield: 73.10%;
mp: 132–134; IR (KBr): 3307 (CAN), 2361 (CAH), 1604
(C‚N), 1580 (NAN), 1554(C‚C), (CAF) 971 cm1; 1H
NMR (300 MHz, CDCl3) d ppm: 3.32 (s, 3H, N-CH3), 4.36
(s, 2H, Ph-CH2), 6.41–6.48 (m, 3H, ArAH),7.14–7.32 (m,
4H, ArAH of Benzim), 8.58 (s, 1H, N‚CHANACH of
1,2,4-Triazole); ESI–MS m/z: 325, 286, 145. Anal. Calcd. for
C18H16F2N6 (354): C, 61.01; H, 4.55; F, 10.72; N, 23.72.
Found: C, 62.03; H, 4.32; F, 10.22; N, 23.54.
2.2.5. 10e: 2, 4-diﬂuoro-N-(1-(1-ethyl-1H-benzo[d]imidazol-2-
yl) ethyl)-N-(1H-1, 2, 4-triazol-1-yl) benzenamine
Compound 10e was obtained as a white solid, Yield: 75%; mp:
119–121; IR (KBr): 3306 (CAN), 2364 (CAH), 1602 (C‚N),
1574 (NAN), 1560 (C‚C), (CAF) 965 cm1; 1H NMR
(300 MHz, CDCl3) d ppm: 1.32 (d, 1H, ACHAN), 3.14 (s,
3H, NACH3), 4.13 (q, 3H, AHCACH3), 6.33–6.48 (m, 3H,
ArAH), 7.20–7.42 (d, 3H, ArAH of Benzim), 7.94 (s, 1H,
N‚CHANACH of 1,2,4-Triazole); ESI–MS m/z: 339.117,
300, 195.048, 173. Anal. Calcd. for C19H18F2N6 (368): C,
61.95; H, 4.93; F, 10.31; N, 22.81. Found: C, 61.24; H, 4.38;
F, 10.74; N, 23.02.
2.2.6. 10f: N-(2,4-diﬂuorophenyl)-N-((1-ethyl-1H-benzo[d]
imidazol-2-yl)(phenyl)methyl)-1H-1,2,4-triazol-1-amine
Compound 10f was obtained as a white solid, Yield: 69%; mp:
189–191; IR (KBr): 3288 (CAN), 2345 (CAH), 1615 (C‚N),
1571 (NAN), 1545 (C‚C), (CAF) 975 cm1; 1H NMR
(300 MHz, CDCl3) d ppm: 3.68 (s, 3H, NACH3), 4.24 (s,
5H, ArAH), 6.43–6.51 (m, 3H, ArAH), 7.26–7.30 (d, 1H,
ACAH), 7.26–7.30 (d, 3H, ArAH of Benzim), 8.02 (s, 1H,
N‚CHANACH of 1,2,4-Triazole); ESI–MS m/z: 401.133,
362, 235. Anal. Calcd. For C24H20F2N6 (430): C, 66.97; H,
4.68; F, 8.83; N, 19.52. Found: C, 66.81; H, 4.12; F, 9.32; N,
20.02.ngal evaluation of novel benzimidazole tertiary amine type of ﬂuconazole ana-
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Figure 7 Binding mode of compound 10e in active site of
modeled CYP51 of Candida albicans.
Figure 8 In vitro antifungal activity against Candida albicans.
8 R.S. Kankate et al.2.2.7. 10g: N-(6-chloro-1-methyl-1H-benzo[d]imidazol-2-yl)
methyl)-2,4-diﬂuoro-N-(1H-1,2,4-triazol-1-yl) benzenamine
Compound 10g was obtained as a white solid, Yield: 64%; mp:
185–187; IR (KBr): 3315 (CAN), 2355 (CAH), 1508 (C‚N),
1564 (NAN), 1566 (C‚C), (CAF) 970, (CACl) 789 cm1;
1H NMR (300 MHz, CDCl3) d ppm: 3.10 (s, 3H, NACH3),
4.37 (s, 2H, PhACH2), 6.40–6.58 (m, 3H, ArAH), 7.20–7.50
(d, 3H, ArAH of Benzim), 8.15 (s, 1H, N‚CHANACH of
1,2,4-Triazole); ESI–MS m/z: 374.8, 359.062, 306.061,
195.048, 179.038. Anal. Calcd. for C17H13ClF2N6 (374.8): C,Scheme 1 Synthesis of tertiary amine type of substituted benzimida
R = H; c: X = Cl, R = H; d: X = H, R = CH3; e: X = OH, R =
R= Phenyl; i: X = Cl, R = Phenyl. Reagents and conditions: (i) K2
mono chloro acetic acid, methanol, reﬂux; (iv) lactic acid/mandelic
dichloromethane, stir; (vii) 1H, 2,4-triazole, K2CO3, toluene; (viii) trie
Please cite this article in press as: Kankate, R.S. et al., Design, synthesis and antifu
logues. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.201554.48; H, 3.50; Cl, 9.46; F, 10.14; N, 22.42, Found: C, 54.39;
H, 3.58; Cl, 9.41; F, 10.11; N, 22.16.
2.2.8. 10h:N-(1-(6-chloro-1-methyl-1H-benzo[d]imidazol-2-yl)
ethyl)-2,4-diﬂuoro-N-(1H-1,2,4-triazol-1-yl) benzenamine
Compound 10h was obtained as a white solid, Yield: 58 %;
mp: 144–146; IR (KBr): 3301 (CAN), 2365 (CAH), 1604
(C‚N), 1584 (NAN), 1556 (C‚C), (CAF) 975, (CACl)
789 cm1; 1H NMR (300 MHz, CDCl3) d ppm: 1.49 (d, 1H,
ACHAN), 3.18 (s, 3H, NACH3), 4.24 (q, 3H, AHCACH3),
6.43–6.51 (m, 3H, ArAH), 7.26–7.30 (d, 3H, ArAH of Ben-
zim), 8.02 (s, 1H, N‚CHANACH of 1,2,4-Triazole); ESI–
MS m/z: 370.1, 355.112, 302.11, 195.048. Anal. Calcd. For C18-
H15ClF2N6 (388): C, 55.60; H, 3.89; Cl, 9.12; F, 9.77; N, 21.62.
Found: C, 55.40; H, 3.81; Cl, 9.08; F, 9.17; N, 21.42.zole derivatives. Compound 10: a: X = H, R =H; b: X = OH,
CH3; f: X = Cl, R = CH3; g: X = H, R= Phenyl; h: X = OH,
CO3, DMF, methylamine; (ii) ammonium chloride, zinc dust; (iii)
acid, methanol, reﬂux; (v) thionyl chloride; (vi) ethanol, KOH,
thylamine.
ngal evaluation of novel benzimidazole tertiary amine type of ﬂuconazole ana-
.02.002
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(phenyl)methyl)-N-(2,4-diﬂuorophenyl)-1H-1,2,4-triazol-1-
amine
Compound 10i was obtained as a white solid, Yield: 63 %; mp:
157–159; IR (KBr): 3280 (CAN), 2367 (CAH), 1607 (C‚N),
1584 (NAN), 1536 (C‚C), (CAF) 972, (CACl) 788 cm1;
1H NMR (300 MHz, CDCl3) d ppm: 3.68 (s, 3H, NACH3),
4.24 (s, 5H, ArAH), 6.43–6.51 (m, 3H, ArAH), 7.26–7.30 (d,
1H, ACAH), 7.26–7.30 (d, 3H, ArAH of Benzim), 8.02 (s,
1H, N‚CHANACH of 1,2,4-Triazole); ESI–MS m/z:
401.133, 221.108, 303.136. Anal. Calcd. For C23H17ClF2N6
(450.1): C, 61.27; H, 3.80; Cl, 7.86; F, 8.43; N, 18.64. Found:
C, 61.24; H, 3.76; Cl, 7.26; F, 8.33; N, 18.61.
2.2.10. 10j: N-(6-chloro-1-ethyl-1H-benzo[d]imidazol-2-yl)
methyl)-2,4-diﬂuoro-N-(1H-1,2,4-triazol-1-yl) benzenamine
Compound 10j was obtained as a white solid, Yield: 64%; mp:
185–187; IR (KBr): 3312 (CAN), 2341 (CAH), 1513 (C‚N),
1571 (NAN), 1560 (C‚C), (CAF) 979, (CACl) 765 cm1;
1H NMR (300 MHz, CDCl3) d ppm: 3.18 (s, 3H, NACH3),
4.21 (s, 2H, PhACH2), 6.54–6.79 (m, 3H, ArAH), 7.30–7.64
(d, 3H, ArAH of Benzim), 8.24 (s, 1H, N‚CHANACH of
1,2,4-Triazole); ESI–MS m/z: 359, 320, 195.048, 275. Anal.
Calcd. for C17H13ClF2N6 (388): C, 55.60; H, 3.89; Cl, 9.12;
F, 9.77; N, 21.62. Found: C, 55.45; H, 3.74; Cl, 9; F, 9.69;
N, 21.29.
2.2.11. 10k: N-(1-(6-chloro-1-ethyl-1H-benzo[d]imidazol-2-yl)
ethyl)-2,4-diﬂuoro-N-(1H-1,2,4-triazol-1-yl) benzenamine
Compound 10k was obtained as a white solid, Yield: 58 %;
mp: 144–146; IR (KBr): 3306 (CAN), 2358 (CAH), 1604
(C‚N), 1586 (NAN), 1552 (C‚C), (CAF) 970, (CACl)
784 cm1; 1H NMR (300 MHz, CDCl3) d ppm: 1.42 (d, 1H,
ACHAN), 3.12 (s, 3H, NACH3), 4.14 (q, 3H, AHCACH3),
6.33–6.48 (m, 3H, ArAH), 7.48–7.65 (d, 3H, ArAH of Ben-
zim), 8.42 (s, 1H, N‚CHANACH of 1,2,4-Triazole); ESI–
MS m/z: 373, 334, 289. Anal. Calcd. For C19H17ClF2N6
(402): C, 56.65; H, 4.25; Cl, 8.80; F, 9.43; N, 20.86. Found:
C, 55.60; H, 4.12; Cl, 9.04; F, 9.25; N, 21.14.
2.2.12. 10l: N-((6-chloro-1-ethyl-1H-benzo[d]imidazol-2-yl)(ph
enyl)methyl)-N-(2,4-diﬂuorophenyl)-1H-1,2,4-triazol-1-amine
Compound 10l was obtained as a white solid, Yield: 63%; mp:
157–159; IR (KBr): 3310 (CAN), 2362 (CAH), 1600 (C‚N),
1581 (NAN), 1532 (C‚C), (CAF) 970, (CACl) 780 cm1;
1H NMR (300 MHz, CDCl3) d ppm: 3.61 (s, 3H, NACH3),
4.17(s, 5H, ArAH), 6.41–6.54 (m, 3H, ArAH), 7.20–7.28 (d,
1H, ACAH), 7.41–7.58 (d, 3H, ArAH of Benzim), 8.12 (s,
1H, N‚CHANACH of 1,2,4-Triazole); ESI–MS m/z: 435,
396,351. Anal. Calcd. For C24H19ClF2N6 (464): C, 62.00; H,
4.12; Cl, 7.63; F, 8.17; N, 18.08. Found: C, 61.91; H, 3.88;
Cl, 7.62; F, 8.22; N, 18.01.
2.3. Invitro antifungal activity
The stock solution of (1 lmole/ml) compounds (equimolar
mixture) was prepared in DMSO and water. To each tube con-
taining sterilized sabouraud’s liquid medium (2 ml), 2 ml of
drug solution was added. Each tube was inoculated with the
microorganism and was kept at 30 C for 14 days.Please cite this article in press as: Kankate, R.S. et al., Design, synthesis and antifu
logues. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015The solutions were ﬁrst tested at the concentration of
0.5 lmole/ml. The sets, which are found active at this concen-
tration, were again tested at concentration of 0.25 lmole/ml.
The groups, which were found active, were subjected to serial
dilutions. The serial dilutions were made to obtain concentra-
tions 0.5, 0.25, 0.125, 0.0625, 0.0314, 0.0152 and 0.0076 lmole/
ml. Positive control tubes (organism + broth + DMSO) and
negative control tubes (broth + drug) were also prepared.
Each tube was inoculated with the microorganism.
All the tubes were incubated at 30 C for 14 days. The read-
ings were taken as expressed as () if inhibition of growth is
seen and (+) if inhibition of growth is not seen Table 3.
2.4. Invivo antifungal study
2.4.1. Animals
Male Wistar rats (8 weeks; approximately 200 g) were used in
this study. Animals were infected intraperitoneal (IP) with C.
albicans on day 0 (2 · 105 CFU per mouse); this was followed
by IP treatment with test sample. Treatment was given once
daily for 4 days starting from day 4 after infection.
2.4.2. Survival study
Survival of the rats was observed until day 45 after infection.
For comparison, the survival of rats treated with one of the
antifungal agents alone or that received no treatment (untreat-
ed controls) was also observed Tables 4A and 4B.
2.4.3. Kidney burden assay
In parallel, groups of ﬁve rats each were sacriﬁced and the
numbers of CFU in the kidneys of these rats were determined
at the intervals indicated below. Appropriately diluted kidney
homogenates were spread onto the surfaces of SDA plates in
triplicate, and the numbers of colonies were counted after incu-
bation for 2 days at 30 C Table 4C.
2.5. Homology modeling of cytochrome P450 lanosterol 14a-
demethylase of C. albicans
The 3D model structure of cytochrome P450 lanosterol 14a-
demethylase of C. albicans was built using homology model-
ing. Amino acid sequence of enzyme was obtained from the
Universal Protein Resource (http://www.uniprot.org/) (Acces-
sion Code: P10613), and sequence homologous was obtained
from Protein Data Bank (PDB) using Blast search. In lit-
erature (Monk et al., 2014), the structure of cytochrome
P450 lanosterol 14a-demethylase was developed homologically
using crystal structure of lanosterol 14a-demethylase from
Saccharomyces cerevisiae YJM 789 as template (531 amino
acid residues). Based on the result of blast search, we used
the crystal structure of Saccharomyces cerevisiae YJM 789
lanosterol 14a-demethylase (CYP51) with intact transmem-
brane domain bound to itraconazole as a template for homol-
ogy modeling (PDB ID. 4K0F, RESOLUTION. 2.19 A˚). The
sequence alignment of 4K0F was done using discovery studio
showed identity 55.9% and similarity 70.2% with our target
sequence Fig. 2. Further, the homology modeled protein
Fig. 3 energy minimization and loop reﬁnement are carried
out by applying CHARMm force ﬁelds and smart minimiza-
tion algorithms followed by conjugate gradient algorithmsngal evaluation of novel benzimidazole tertiary amine type of ﬂuconazole ana-
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were performed by discovery studio (Lovell et al., 2003).
Geometric evaluations of the modeled 3D structure were
performed using Rampage Fig. 4A and B. The Ramachandran
plot of our model showed that 96.6% of residues were in the
favor, 3% allowed regions, and 0.4% was in the outlier region
as compared to 4K0F template (98%, 2%, and 0%). The plot
statistics are presented in Table 1.
Validation was carried out using ProSA to obtain the
Z-score value for the comparison of compatibility Fig. 5.
The Z-score plot showed spots of Z score values of proteins
determined by NMR (represented in dark blue color) and by
X ray (represented in light blue color). The two black dots rep-
resent Z-scores of our model (7.46) and template (7.58).
These scores indicate the overall quality of the modeled 3D
structure of lanosterol 14-alpha demethylase of C. albicans.
RMSD (0.38 A˚) was calculated between the main chain atom
of model and template. It indicated close homology. This
ensured the reliability of the model. Superimposition between
target and template structure was done using SPDBV Fig. 6.
3. Results and discussion
3.1. Synthesis
The targeted compounds were synthesized by a seven-step
reaction process (Scheme 1). The 4-substituted N1-alkyl-2-ni-
troaniline 2 was synthesized by using 4-substituted 2-chloroni-
trobenzene 1, anhydrous potassium carbonate, alkylamine and
dimethyl formamide (DMF) as solvent in microwave. The
nitro group of phenyl ring 2 was further reduced to amino
group in presence of ammonium chloride and zinc dust to give
3. Further this synthesized 3a–d and mono chloro acetic/lac-
tic/mandelic acid dissolved in methanol, HCl and reﬂux in
microwave to give 4a–d and 5a–h. Then activation of
carboxylic functional group of 5a–h was carried out by using
thionyl chloride and catalytic amount of DMF to give 6a–h.
2, 4-Diﬂuroaniline and dichloromethane were dissolved in
ethanol and stirred on Rota mental at 750 C to give 8. Further
8 reacted with 1H, 2, 4-triazole in presence of NaOH and
DMF to give 9. The target compounds 10a–i were obtained
by reacting 9 and 4a–d, 6a–h, in the presence of triethylamine.
3.2. Docking
The ligand ﬁt method was performed to study and predict the
binding mode of newly synthesized compounds with the target
enzyme (homology modeled) cytochrome P450 lanosterol 14-
a-demethylase of C. albicans. All compounds showed binding
in the active site of the enzyme. The 1, 2, 4-triazole ring (com-
pounds 10a–10l) is positioned almost perpendicular to the por-
phyrin plane, with a ring nitrogen (N-4) atom coordinated to
the heme iron (Fig. 7). The distance between nitrogen of azole
ring in all compounds and heme ring was measured and found
in the range of 2.16–3.19 and was comparable with that found
in the crystal structure of human lanosterol 14a-demethylase
complexed with azole inhibitors Table 2. The 1, 2, 4-triazole
ring nitrogen atom (N2) forms hydrogen bonding with amino
acid CYS 470. The tertiary amine group showed hydrogen
bonding with SER378. In most of the compounds, dihalophe-
nyl ring occupied the same hydrophobic region above the hemePlease cite this article in press as: Kankate, R.S. et al., Design, synthesis and antifu
logues. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015ring and showed good Vander Waals interaction with heme
and amino acids ILE304, LYS143, and GLY450, whereas sub-
stituted benzimidazole ring of most of compounds located near
hydrophobic region by making good Vander Waals interaction
with HIS 310, THR311, VAL488, and MET508. In particular,
all hydrophobic substituents ﬁnd location in a hydrophobic
sub-site above the heme ring.
3.3. Biological activity
Antifungal activity of the synthesized compounds was tested
against candida albicans spores in vitro and in vivo. In vitro anti-
fungal activity was evaluated using the tube dilution method
(Cappucino and Sherman, 1996; Pernaka et al., 2001) (turbidi-
metric method). The turbidimetric method depends on the inhi-
bition of growth in a microbial culture of uniform solution
containing the drug in ﬂuid medium favorable for rapid
growth. In this method, minimal inhibitory concentration
(MIC) of the antifungal agent was determined. The MIC is
the lowest concentration of an antimicrobial agent that inhibits
the test organism. The growth in the tube was observed visually
for turbidity and inhibition was determined by the absence of
growth. In the present study, C. albicans (ATCC10232) was
used to investigate the activity. Fluconazole and dimethyl
sulphoxide were used as standard and solvent respectively.
The antifungal activity clearly indicated that 10i has a good
antifungal activity as compared with the other twelve com-
pounds at 0.0075 lmole/ml which is equivalent to ﬂuconazole
activity as far as the in vitro results are concerned. The activity
decreased with the increasing alkyl length of N1 of benzimida-
zole (methyl to ethyl). This was proven with compounds 10i
and 10l which showed MICs of 0.0075 and 0.015 lmoles/ml
respectively Fig. 8.
C. albicans induced candidiasis in rats was used to investi-
gate the in vivo antifungal activity of test samples. It is also
proposed that kidney is one of the prime organs affected by
fungal infection in in vivo models. In systemic candidiasis, kid-
ney is the major site of multiplication of C. albicans. The ani-
mals were infected with C. albicans and fungal load was
characterized on the basis of kidney burden of C. albicans.
Kidney homogenate was serially diluted to get proper results
to count colonies of C. albicans. Colony forming units
(CFU) in kidney homogenate of animals treated with standard
drug and test samples were signiﬁcantly less (P< 0.001) as
compared to vehicle treated animals. All test samples were
effective at 0.26 and 0.42 mg/kg. Compound 10i showed the
most superior activity. CFU in kidney homogenate of com-
pound 10i treated animals was signiﬁcantly less (P< 0.001)
as compared to other treatments. The results conﬁrmed that
10i was more potent as compared with the other compounds.
Signiﬁcantly lesser value of fungal burden in kidney of test
sample treated animals conﬁrmed antifungal potential of test
samples.4. Conclusion
In conclusion, a new scaffold has been proposed for potential
antifungal activity. Benzimidazole derivative with N1 methyl,
C2 as asymmetric center, C5 chlorine substitutions, tertiary
amine and 1,2,4-triazole showed good docking score and
antifungal activity. This may be due to increase in basicity ofngal evaluation of novel benzimidazole tertiary amine type of ﬂuconazole ana-
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benzimidazole. Docking scores and antifungal activity of these
compounds have been justiﬁed by investigating their interac-
tion at the active site of CYP51. The 1,2,4-triazole ring is posi-
tioned almost perpendicular to the porphyrin plane, with a
ring nitrogen (N-4) atom coordinated to the heme iron and
nitrogen atom (N2) forms hydrogen bonding with amino acid
CYS 470. The tertiary amine group showed hydrogen bonding
with SER378. The structural difference of these compounds
from the ﬂuconazole can make them less prone to the develop-
ment of resistance by pathogenic fungal strain against them. A
meaningful SAR has been developed.
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